Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00741455 · ClinicalTrials.gov registry record · NA
Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies
A NA study, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT00741455 is a NA study that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 18 participants.
The verdict
NCT00741455, a NA study, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to determine disease-free survival, overall survival, time to progression, regimen-related toxicity and/or treatment-related mortality in patients with hematologic malignancies treated with non-myeloablative chemotherapy followed by allogeneic stem cell transplant.
Interventions
- DRUG Fludarabine
- DRUG G-CSF
- DRUG Cyclosporine
- DRUG cyclophosphamide
- PROCEDURE Stem Cell Transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2004-06 |
| Est. Completion | 2020-05-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00741455
The ClinicalTrials.gov registry entry for NCT00741455 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT00741455 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00741455 about?
NCT00741455 is a clinical study titled "Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies". The purpose of this study is to determine disease-free survival, overall survival, time to progression, regimen-related toxicity and/or treatment-related mortality in patients with hematologic malignancies treated with non-myeloablative chemotherapy followed by allogeneic stem cell transplant.
What is the current status of trial NCT00741455?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2004-06. Estimated completion is 2020-05-01.
What interventions are being tested in trial NCT00741455?
The interventions under investigation include: Fludarabine (DRUG), G-CSF (DRUG), Cyclosporine (DRUG), cyclophosphamide (DRUG), Stem Cell Transplant (PROCEDURE).
Who is sponsoring clinical trial NCT00741455?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.